News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Active Pass Pharmaceuticals Receives $3.6 Million CDN Grant From NIH For Development Of Novel Treatment For Secretory Diarrhea


10/19/2005 5:08:44 PM

Active Pass Pharmaceuticals today announced receipt of a grant of $3.6 M CDN ($2.8 M USD) for development of a novel treatment for secretory diarrhea. The award was made by the National Institute of Allergy and Infectious Diseases (NIAID) branch of the National Institute of Health (NIH) in the United States. Dr. David MacDonald, President and CEO of Active Pass, is the principal investigator.

Read at BioSpace.com

comments powered by Disqus
   
Diarrhea

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES